{"entity":{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","aka":[],"tldr":"Tests whether a two-armed antibody against EGFR and a stem-cell marker can lift first-line immunotherapy results in head and neck cancer.","summary":"Phase 2 petosemtamab + pembrolizumab reported ORR ~63% in first-line PD-L1-positive HNSCC (ASCO 2025), far above pembrolizumab's historical ~19-23%. LiGeR-HN1 (first line, includes HPV-positive disease) and LiGeR-HN2 (second line, monotherapy vs chemotherapy) are the registrational trials; interim analyses expected 2026-27.","status":"recruiting","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT06525220","url":"https://clinicaltrials.gov/study/NCT06525220"}],"tags":[],"related":[],"cancers":["head-and-neck","recurrent-metastatic-hnscc"],"sections":[],"technologies":["bispecific-antibody"],"targets":["egfr","lgr5"],"drugs":["petosemtamab","pembrolizumab"],"companies":["merus","genmab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06525220","phase":"3","setting":"Untreated PD-L1-positive recurrent or metastatic HNSCC: petosemtamab + pembrolizumab vs pembrolizumab","sponsor":"Merus (Genmab)","participation":[{"nct":"NCT06525220","source":"https://clinicaltrials.gov/study/NCT06525220","fetchedAt":"2026-10-07T16:54:46.480Z","studySha256":"02b0ecd188242dc0ce6409683953f96a29c0ff71489b4fc86976d040f2ba8ba4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Merus B.V.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":699,"enrolmentType":"ACTUAL","siteCount":202,"recruitingSiteCount":0,"countries":["Argentina","Australia","Belgium","Brazil","Canada","Chile","Croatia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Lithuania","Malaysia","Mexico","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-09-25","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/liger-hn1/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"term":[{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/"}],"pairing":[{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/"}]}}